What are the details of the nationwide blood pressure medication recall

On 28 October 2026, the U.S. Food and Drug Administration announced a significant expansion of a nationwide recall affecting several widely prescribed blood pressure medications, specifically those within the angiotensin II receptor blocker (ARB) class. The recall was initiated following the discovery of trace amounts of nitrosamine impurities, which are classified as potential human carcinogens, exceeding the agency's acceptable daily intake limits. Pharmaceutical manufacturers involved in the recall have identified that the contamination likely originated from specific chemical synthesis processes used at international manufacturing facilities. The affected products include various dosages of valsartan, losartan, and irbesartan distributed to pharmacies across the United States over the past six months. Health officials are urging patients currently taking these medications not to discontinue their treatment abruptly, as doing so could lead to dangerous spikes in blood pressure or cardiovascular events. Instead, patients are advised to consult their healthcare providers immediately to arrange for a safe transition to alternative, non-recalled medications. Pharmacies have been instructed to quarantine all remaining stock and notify patients who received the impacted batches.